NEOG · Neogen Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Neogen Corporation shareholders approved its Amended and Restated Omnibus Incentive Plan on October 1, 2026, authorizing equity-based awards and up to 31,350,000 shares.
Neogen reported positive core growth for four consecutive quarters and strategic accounts up 6.2 percent year to date, targeting eight plus percent by year end. Its strategy centers on commercial prowess, high-impact innovation and operational excellence.
Neogen Corporation reported $13.6 million revenue growth and 47.4% gross margin for the three months ended August 31, 2026; the Genomics sale remained under ACCC and NZCC review expected to conclude by the end of December 2026.
Neogen Corporation shareholders approved executive compensation, ratified BDO USA, P.C., and approved the amended incentive plan and an Employee Stock Purchase Plan amendment increasing shares available for issuance at the 2026 Annual Meeting.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q4 FY26 earnings call · Jul 30, 2026TL;DR. Neogen reported Q4 FY26 core revenue growth of 4.3% led by Food Safety at 5.8% core growth, its highest since FY23, with adjusted EBITDA of $45.4 million (20.2% margin) and free cash flow of $26.2 million; the company provided FY27 guidance of $880-$885 million revenue and $180-$182 million adjusted EBITDA while planning a 50% R&D increase, a Petrifilm manufacturing transition starting November 2026, and the Petrifilm first SKU validation by end of August.
- + Q4 Food Safety core growth of 5.8%, highest since FY23, with Bacterial & General Sanitation up 9.9% and Indicator Testing/Culture Media up 9.5%
- + Adjusted gross margin expanded 330 bps year-over-year to 49.7%
- + FY27 revenue guidance of $880-$885 million implies ~3% core growth and adjusted EBITDA of $180-$182 million, with management noting $30 million above prior street consensus
- + Inventory reduced by more than $36 million year-over-year and on-time/full delivery improved 40% since launching SNOP
- + R&D investment increasing ~50% in FY27 with long-term objective of approaching 5% of revenue
- − FY27 reported revenue growth implication is only ~1.5% after ~50 bps divestiture headwind and ~100 bps negative FX
- − FY27 adjusted EBITDA margin of 20.5% at midpoint implies only slight expansion vs FY26 as investments absorb efficiencies
- − Customer inflation pressures from Iran war temper near-term volume outlook despite positive industry volume trends
- − FY27 transformation initiatives expected to total $25 million, up from ~$22 million in FY26
- − Genomics divestiture regulatory review moved into second phase in Australia and New Zealand, extending closing timeline risk
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Earnings Per Share non-GAAP | $0.08 | Q1 FY27 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | $41.6M | Q1 FY2027 | — |
|
|
|||
| Adjusted EBITDA Margin non-GAAP | 18.7% | Q1 FY2027 | — |
|
|
|||
| Adjusted Gross Profit non-GAAP | $110.9M | Q1 FY27 | — |
|
|
|||
| Adjusted Net Income non-GAAP | $17.5M | Q1 FY27 | — |
|
|
|||
| Adjusted Operating Expenses non-GAAP | $74.4M | Q1 FY27 | — |
|
|
|||
| Adjusted Operating Income non-GAAP | $36.5M | Q1 FY27 | — |
|
|
|||
| Animal Safety Core Growth non-GAAP | 8% | Q1 FY2027 | — |
|
|
|||
| Cash flow from operations | $12.9M | Q1 FY2027 | — |
| Core Growth non-GAAP | 8.1% | Q1 FY2027 | — |
|
|
|||
| Food Safety Core Growth non-GAAP | 8.1% | Q1 FY2027 | — |
|
|
|||
| Free cash flow | $4.7M | Q1 FY2027 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities $12.9M
-$8.2M Purchases of PPE
= Free Cash Flow $4.7M
|
|||
| Animal Safety Core Revenue Growth non-GAAP | 0.5% | Q4 FY26 | — |
| Food Safety Core Revenue Growth non-GAAP | 3.1% | FY26 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NEOG
this stock
Neogen Corp
|
$2.38B | +55.7% | -2.7% | — | 5.8% |
|
ABT
Abbott Laboratories
|
$186.10B | -14.2% | +5.7% | 40.1 | 1.1% |
|
MDT
Medtronic plc
|
$131.60B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$118.29B | -11.6% | +11.2% | 33.1 | 1.7% |
|
BSX
Boston Scientific Corp
|
$63.33B | -54.2% | +12.5% | 18.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NEOG | -9.9% | -6.5% | +18.3% | -8.0% | +55.7% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -8.2% | -3.0% | +19.7% | -5.9% | +47.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.